Conivaptan is a non-peptide vasopressin V1a and V2 receptor antagonist used to treat euvolemic and hypervolemic hyponatremia by promoting free water excretion. To support the rigorous demands of pharmaceutical… Read more

























Conivaptan is a non-peptide vasopressin V1a and V2 receptor antagonist used to treat euvolemic and hypervolemic hyponatremia by promoting free water excretion. To support the rigorous demands of pharmaceutical quality control, this category provides a comprehensive range of reference standards, including the active pharmaceutical ingredient, identified impurities, metabolites, and stable isotope labelled compounds. Laboratories utilize these high-quality materials for impurity profiling, method validation, and routine assay testing to ensure the safety and efficacy of the drug product throughout its lifecycle. By employing these specific reference standards during analytical procedures, researchers can accurately identify and quantify degradants and synthesis-related byproducts, satisfying regulatory requirements for comprehensive stability monitoring and structural characterization. This collection assists chemists in developing reliable analytical methods for the precise evaluation of Conivaptan and its related substances in complex pharmaceutical matrices.